Haemonetics (HAE) Q2 2027 Earnings Call Transcript

Haemonetics reported Q2 FY2027 organic revenue growth of 10% and adjusted EPS of $1.35, up 6.3% year over year, and raised full-year organic revenue guidance to 6%-9% from 4%-7%. Apheresis organic revenue guidance increased to high single digits, supported by plasma growth and the CSL rollout, while adjusted operating margin expansion guidance was cut to 0-50 basis points from 50-100 basis points because of capacity investments, performance-based compensation and inflationary pressures. First-half operating cash flow rose 40% to $180 million and free cash flow increased 57% to $143 million; management expects the CSL ramp and related operating leverage to contribute more substantially in fiscal 2028 and beyond.

Analysis

The key issue is conversion economics, not demand: capacity, devices and logistics are being funded before CSL volumes fully ramp, so earnings may lag revenue through the near term. Gross-margin quality is less strong than the headline suggests: excluding tariff refunds and FX, underlying gross margin was roughly flat, while elevated operating costs and production costs flowing out of inventory could weigh on the second half. Management’s operating-leverage case is plausible, but FY2028 is the proof point, not a current earnings contribution.

The less-obvious demand risk is that Persona PLUS improves yield per collection. That helps customers’ cost per liter, but could let some collectors meet near-term needs with fewer donations—potentially tempering equipment and disposable demand before collections normalize. Conversely, broader adoption and recurring TEG disposables improve revenue durability, partly offsetting the fading capital-upgrade cycle. PerQseal Elite is a longer-dated option; physician training and launch execution matter more than the stated market opportunity.

Time horizon: near term, expect margin and cash-investment scrutiny despite better revenue visibility; over 1–3 months, watch confirmed CSL conversion dates and fourth-quarter delivery; over 6–18 months, test whether higher throughput yields fixed-cost absorption without collection or rollout slippage. The consensus risk is treating management’s FY2028 leverage expectation as already earned. Falsifiers include conversion delays, weaker plasma collection trends, inventory/cash conversion deterioration, or no margin improvement as volumes scale.

Key Decisions for Investors

• Do not chase the revenue-guidance increase alone. Prefer entry on post-earnings weakness only if CSL conversion milestones remain on schedule and working-capital trends hold; upside depends on FY2028 leverage, while near-term margin disappointment is the key downside.
• Treat the margin outlook as a watch item, not a confirmed inflection: track quarterly gross margin excluding tariff-related benefits, inventory growth, freight costs and free-cash-flow conversion. Reassess the long thesis if margins fail to improve as ramp costs subside.
• Monitor plasma collections alongside Persona PLUS adoption. If yield gains coincide with slower collection volumes or weaker consumable demand, reduce expectations for near-term plasma growth; sustained collections plus confirmed conversions would strengthen the multi-year case.
• No high-conviction pair trade is warranted from this transcript alone; verify valuation, post-call price action and reported segment economics before sizing an outright position.